April 6th, 2010 - 09:30 GMT Merck Serono: Erbitux granted extended use in Japan for 1st-line treatment of mCRC Patients with KRAS wild-type tumors Approval of change in product information is based on the data of the Phase III CRYSTAL trial Read more
